Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy

Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy

The PARP inhibitor olaparib has been approved in the maintenance setting of platinum-sensitive epithelial ovarian cancer patients with germline or somatic <i>BRCA1/2</i> mutation. Therefore, the availability of a tumor BRCA test has become a clinical need. We report the results of the cl...

Full description

Bibliographic Details
Main Authors: Caterina Fumagalli, Federica Tomao, Ilaria Betella, Alessandra Rappa, Mariarosaria Calvello, Bernardo Bonanni, Loris Bernard, Fedro Peccatori, Nicoletta Colombo, Giuseppe Viale, Massimo Barberis, Elena Guerini-Rocco
Format: Article
Language:English
Published: MDPI AG 2019-10-01
Series:Cancers
Subjects:
<i>brca1/2</i>
ovarian cancer
next-generation sequencing
Online Access:https://www.mdpi.com/2072-6694/11/11/1641

Internet

https://www.mdpi.com/2072-6694/11/11/1641

Similar Items